These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 8765676

  • 21. The history and background of Augmentin.
    Rolinson GN.
    S Afr Med J; 1982 Jul 28; 62(5 Spec No):3A-4A. PubMed ID: 6979804
    [Abstract] [Full Text] [Related]

  • 22. Basic design of beta-lactam antibiotics: penams and analogues and monocyclic beta-lactams.
    Ekström B.
    Scand J Infect Dis Suppl; 1984 Jul 28; 42():38-49. PubMed ID: 6335599
    [Abstract] [Full Text] [Related]

  • 23. 3-Methylidene-beta-lactams as potential inhibitors of beta-lactamases. Part 1: Synthesis of alpha-substituted derivatives from imines by Reformatzky reaction with chlorotrimethylsilane, silylation and Peterson olefination.
    Gürtler S, Ruf S, Johner M, Otto HH.
    Pharmazie; 1996 Nov 28; 51(11):811-5. PubMed ID: 8985976
    [Abstract] [Full Text] [Related]

  • 24. [Antibacterial activity of beta-lactamase inhibitors and selected beta-lactam antibiotics].
    Jastalska D, Lupicki W, Pajchel G, Zapaśnik M, Chojnowski W.
    Pol Tyg Lek; 1986 Aug 25; 41(34):1071-5. PubMed ID: 3097627
    [No Abstract] [Full Text] [Related]

  • 25. Evolution of beta-lactamase inhibitors.
    Rolinson GN.
    J Reprod Med; 1988 Jun 25; 33(6 Suppl):571-3. PubMed ID: 3294401
    [Abstract] [Full Text] [Related]

  • 26. Structure-based design of beta-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins.
    Hubschwerlen C, Angehrn P, Gubernator K, Page MG, Specklin JL.
    J Med Chem; 1998 Oct 08; 41(21):3972-5. PubMed ID: 9767634
    [Abstract] [Full Text] [Related]

  • 27. Synthesis of 3-Substituted-clavams: Antifungal Properties, DD-Peptidase and beta-Lactamase Inhibition.
    Cierpucha M, Panfil I, Danh TT, Chmielewski M, Kurzatkowski W, Rajnisz A, Solecka J.
    J Antibiot (Tokyo); 2007 Oct 08; 60(10):622-32. PubMed ID: 17965478
    [Abstract] [Full Text] [Related]

  • 28. N-pyrrylderivatives of penicillins. Kinetics and inhibition studies with clavulanic acid of a Bacillus cereus beta-lactamase.
    Díez MT, Arín MJ, Negro A, Salto F.
    Pharmazie; 1987 Jun 08; 42(6):415-6. PubMed ID: 3118398
    [No Abstract] [Full Text] [Related]

  • 29. [Mechanisms of resistance to beta-lactam inhibitors of beta-lactamases].
    Blázquez J.
    Rev Esp Quimioter; 1998 Dec 08; 11(4):368-9. PubMed ID: 10336318
    [No Abstract] [Full Text] [Related]

  • 30. Effects of beta-lactamase inhibitors on Staphylococcus aureus susceptibility to penicillin G and penicillinase-resistant penicillins.
    Montanari MP, Varaldo PE.
    J Chemother; 1989 Jul 08; 1(4 Suppl):344-5. PubMed ID: 16312431
    [No Abstract] [Full Text] [Related]

  • 31. In vitro activity of some beta-lactams in combination with dicloxacillin against Mycobacterium fortuitum.
    Fattorini L, Amicosante G, Fiorentino D, Franceschini N, Oratore A, Orefici G.
    J Chemother; 1989 Jul 08; 1(4 Suppl):339-41. PubMed ID: 16312429
    [No Abstract] [Full Text] [Related]

  • 32. [Indicator method of determining the beta-lactamase-inhibiting activity of various compounds].
    Ivanitskaia LP, Nikishina VG.
    Antibiotiki; 1981 Apr 08; 26(4):259-64. PubMed ID: 6972191
    [Abstract] [Full Text] [Related]

  • 33. [Characterization of the resistance to combinations of beta lactams and inhibitors of beta-lactamases in Escherichia coli. Effect of the type and amount of beta-lactamase production].
    del Mar Pérez-Moreno M, Pous-Miralles G, Romera-Sastre G, Panisello-Bertomeu JM, Jardí-Baiges AM, Zarazoga-López J.
    Enferm Infecc Microbiol Clin; 1997 Nov 08; 15(9):477-81. PubMed ID: 9527373
    [Abstract] [Full Text] [Related]

  • 34. The use of in vitro kinetic models in the evaluation of beta-lactamase inhibitors.
    White A, Cooper C, Stokes D.
    Chemioterapia; 1987 Jun 08; 6(2 Suppl):202-4. PubMed ID: 3509934
    [No Abstract] [Full Text] [Related]

  • 35. [Beta-lactamase inhibitors and their possible therapeutic significance].
    Fomina IP, Lobuseva AN, Navashin SM.
    Antibiotiki; 1984 Feb 08; 29(2):142-8. PubMed ID: 6367631
    [No Abstract] [Full Text] [Related]

  • 36. Sensitivity of clinical bacterial isolates to Timentin (ticarcillin/clavulanic acid).
    Villiger JW.
    N Z Med J; 1986 Nov 26; 99(814):914. PubMed ID: 3492692
    [No Abstract] [Full Text] [Related]

  • 37. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.
    Wise R, Andrews JM, Bedford KA.
    J Antimicrob Chemother; 1980 Mar 26; 6(2):197-206. PubMed ID: 6247316
    [No Abstract] [Full Text] [Related]

  • 38. [Preliminary evaluation of the sensitivity of selected bacteria to amoxicillin and augmentin in comparison with other antibiotics used to date].
    Ruczkowska J, Dolna I.
    Przegl Lek; 1984 Mar 26; 41(4):321-4. PubMed ID: 6565294
    [No Abstract] [Full Text] [Related]

  • 39. Initial results of in vitro studies of clavulanic acid synergism.
    Li JT, Feng M, Ma LJ, Tao WY, Wang S.
    Chin Med J (Engl); 1981 Sep 26; 94(9):617-21. PubMed ID: 6793329
    [No Abstract] [Full Text] [Related]

  • 40. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb 26; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.